2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6309 Impact of geographic distances on bispecific antibody (bsAb) dose intensity and clinical outcomes in relapsed/refractory multiple myeloma (RRMM)

Katherine Zhuo, MD, Kara Cicero Jr, MD, MPH2, Madhav V. Dhodapkar, MD3, Danai Dima, MD4, Laahn Foster, MD5, Mary Kwok, MD6, Richa Thakur, MD7, Rahul Banerjee, MD8, Andrew J. Portuguese, MD9
1 University of Washington, Seattle, Washington, United States
2 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
6 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
8 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
9 Fred Hutch Cancer Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Background: While bsAbs have many advantages as off-the-shelf treatment options for RRMM, the frequent dosing schedule can be challenging for patients with long driving distances. Far-residing patients may preferentially opt for inpatient step-up dosing (SUD) even if they are candidates for outpatient SUD, thereby contributing to rising healthcare costs. With CAR-T therapy, a related RRMM modality, several studies have noted the negative impact of long geographic distances on access to therapy (Ahmed TCT 2022; Blue CLML 2026; Daunov Blood ICT 2026). It is unknown if long commuting distances lead to early bsAb dose de-escalations in RRMM, which in turn may constitute a risk factor for shortened treatment responses.

Methods: We conducted a retrospective study of patients who received commercial bsAb therapy at our center for RRMM with at least 6 months of dosing data (and/or documented discontinuation or death) before April 2026. Patients were excluded if they received talquetamab specifically for pre-CAR-T bridging or transitioned ongoing bsAb therapy to other centers within 6 months of initiation. Distance was measured from our center to the patient's normalized 5-digit ZIP code and mapped to its Census ZIP Code Tabulation Area. Distances were categorized into tertiles. The primary endpoint was the number of bsAb doses (including SUD) administered from start of bsAb initiation through 6 months after. Time on therapy, progression-free survival (PFS), and overall survival (OS) were estimated using Kaplan-Meier methods. Response, PFS, and OS were compared across tertiles using unadjusted tests. Minimally adjusted models evaluated log-transformed distance in miles as a continuous predictor and adjusted for bsAb agent.

Results: The final cohort included 110 bsAb courses in 94 unique patients who received teclistamab (n=55), talquetamab (n=44), elranatamab (n=6), or linvoseltamab (n=5). The median age was 66 (range: 40-91); 10% of courses were for Asian-American / Pacific Islander (AAPI) patients, 9% for Black patients, and 1% for American Indian patients. Geographic distances ranged from 0 to 1449.3 miles; distance tertiles were classified as 0-12.4 miles (n=37), 12.5-25.6 miles (n=37), and 25.8-1449.3 miles (n=36). There were no significant differences between tertiles in terms of bsAb type; however, AAPI and Black patients were more likely to reside in the closer two tertiles.
Median numbers of bsAb doses administered within the 6-month period were 15, 12, and 10 across increasing tertiles respectively. Distance was not clearly associated with number of doses administered: (rate ratio [RR] 0.97 per log1p mile, 95% CI 0.89-1.05; p=0.438). Inpatient SUD was uncommon and did not differ clearly by distance (13.5%, 8.1%, and 11.1% across tertiles); continuous-distance modeling showed no clear association (OR 0.67, 95% CI 0.39-1.16; p=0.155).
Response did not differ significantly by tertile. ≥VGPR rates were 64.9%, 56.8%, and 44.4% (p=0.210); and ≥PR rates were 73.0%, 62.2%, and 61.1% (p=0.496). Continuous distance was also not associated with ≥PR or ≥VGPR. Median time on drug was 5.3 months overall and was similar across tertiles (5.1, 5.5, and 5.0 months); 6-month on-drug probabilities were 45.9%, 48.6%, and 44.4%. Continuous distance was not associated with discontinuation/death (HR 1.01, 95% CI 0.83-1.23; p=0.919). Median follow-up by reverse Kaplan-Meier was 12.2 months overall. There was no clear distance association with PFS (HR 1.00, 95% CI 0.78-1.28; p=0.984) or OS (HR 0.92, 95% CI 0.60-1.39; p=0.679).

Conclusions: Our study of over 100 bsAb courses did not identify any association between geographic distance, dose intensity, and clinical outcomes in RRMM. Contrary to our hypothesis, inpatient SUD was not more common among far-residing patients. These findings contrast with broader literature involving disparities in RRMM (Banerjee BCJ 2024), much of which has been focused on access to CAR-T therapy. As bsAbs move into earlier lines of therapy with planned dose de-escalations within 6 months of treatment initiation, our findings support their broad applicability even for patients who reside at greater distances from the clinic. Limitations of our study include its retrospective single-center design and selection bias in terms of patients who chose to initiate bsAb therapy. Prospective studies with patient-facing surveys to better assess the impact of driving distances on decision-making are in development.

Katherine Zhuo, MD: No relevant conflicts of interest to declare.